Compare Quantum Computing Inc (QUBT) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quantum Computing Inc vs Recursion Pharmaceuticals Inc — how do they compare? Quantum Computing Inc trades at $8.07 (market cap $1.86B), while Recursion Pharmaceuticals Inc trades at $3.24 (market cap $1.86B). The key difference: Quantum Computing Inc and Recursion Pharmaceuticals Inc are close in size by market cap. Which is the better fit depends on your goals.
| QUBT | RXRX | |
|---|---|---|
Market Cap | $1.86B | $1.86B |
Sector | Technology | Health |
52-Week High | $24.62 | $6.79 |
52-Week Low | $6.31 | $2.84 |
Enterprise Value | $927.53M | $1.38B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quantum Computing Inc. (QUBT) trades at $8.22, up 2.62% today, amid bearish technical signals and challenging fundamentals. The company reported a net loss of $18.67 million on minimal revenue of $682,000 in 2025, with negative profit margins across all metrics. However, analyst sentiment remains optimistic with a 75% buy rating and $19 consensus price target, supported by recent government funding announcements and institutional investments from BlackRock and Bank of New York Mellon.
QUBT offers speculative growth potential in quantum computing but carries significant execution risks. The stock's 131% upside to analyst targets contrasts with persistent losses and high cash burn. Investors face volatility from unproven technology commercialization while banking on long-term quantum adoption. Key catalysts include contract wins and manufacturing scale-up, but profitability remains years away.
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quantum Computing Inc
Quantum Computing Inc. is a company focused on providing accessible quantum computing and quantum-enhanced software solutions for complex problems. The company's technology is designed to run on both classical and quantum hardware, enabling businesses to explore the power of quantum computing today for applications in finance, drug discovery, and logistics. QUBT offers a platform that makes quantum algorithms and software available through the cloud, aiming to democratize access to this advanced computing paradigm.
Read more on QUBT →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
